Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy
|
|
- Harriet Houston
- 6 years ago
- Views:
Transcription
1 Endocrine-Related Cancer (2008) Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy Wei Wang*, Takeshi Yuasa, Norihiko Tsuchiya, Shinya Maita, Teruaki Kumazawa, Takamitsu Inoue, Mitsuru Saito, Zhiyong Ma, Takashi Obara, Hiroshi Tsuruta, Shigeru Satoh and Tomonori Habuchi Department of Urology, Akita University School of Medicine, Hondo, Akita , Japan (Correspondence should be addressed to T Yuasa; yuasa@doc.med.akita-u.ac.jp) *W Wang is now at Department of Urology, Second Affiliated Hospital of SunYat-sen University, Guangzhou, Guangdong province, China Abstract Androgen-deprivation therapy (ADT) of patients with prostate cancer (PCa) is known to reduce bone mineral density (BMD). However, the most studies examined Caucasian or black patients and the effects of ADT on the bone metabolism of East Asians are unclear. Therefore, we performed a crosssectional study to elucidate the influence of ADT on bone metabolism in Japanese patients. In total, 101 native Japanese patients with PCa were enrolled. They consisted of 58 ADT-treated and 43 hormone-naive patients. The BMD in the lumbar spine, total hip, and femoral neck was measured by dual energy X-ray absorptiometry and expressed in S.D. units relative to young adult men (T-score) or age-matched men (Z-score). Serum levels of bone metabolism markers were also measured. The BMDs at the three sites revealed that 2.3% (1/43) and 8.6% (5/58) of the hormone-naive and ADT-treated PCa patients had osteoporosis respectively, but this difference failed to achieve statistical significance (PZ0.294). The two groups also did not differ significantly in their Z-scores of the three sites, and univariate and multivariate analyses indicated that ADT was not a significant risk factor for decreased BMD. In addition, a significant correlation between the duration of ADT and BMD was not observed for all three sites measured. However, the ADT-treated patients had significantly higher serum levels of N-terminal telopeptide of type I collagen (NTx) than the hormone-naive patients (PZ0.017). To our knowledge, this is the first study to demonstrate the low prevalence of osteoporosis in both ADT-treated and hormone-naive Japanese PCa patients. Moreover, ADT did not significantly increase the prevalence of osteoporosis in this Japanese population. Endocrine-Related Cancer (2008) Introduction Androgen-deprivation therapy (ADT) has been the standard treatment for metastatic prostate cancer (PCa), since Huggins & Hodges first reported it in 1941 (Huggins & Hodges 1941). Currently, ADT is used not only to treat metastatic PCa, it is also frequently employed to treat non-metastatic PCa, where it is used either as a mainstream treatment for aging men with local disease or as a treatment for patients with biochemical failure after prostatectomy or radiation therapy (Cooperberg et al. 2003, Sharifi et al.2005, Nelson 2006). In addition, early ADT benefits patients with nodal metastases who have undergone prostatectomy and lymphadenectomy when compared with patients who received ADT later (Messing et al. 2006). Thus, patients are now frequently treated with ADT more often or for longer periods than in the past, which suggests that the adverse effects associated with ADT may become a greater clinical problem in the future. This necessitates more careful delineation and monitoring of the complications of ADT. ADT is associated with anemia, weight gain, insulin resistance, ischemic heart disease, hypogonadism, and increasing bone resorption (Higano 2003, Nelson 2006). Of these ADT complications, increasing bone resorption is of particular concern, because it may lead to osteoporosis and bone fractures (Smith 2004, Shahinian Endocrine-Related Cancer (2008) /08/ q 2008 Society for Endocrinology Printed in Great Britain DOI: /ERC Online version via
2 W Wang et al.: BMD in Japanese prostate cancer patients et al.2005). Indeed, a number of studies have shown that ADT-treated patients with PCa suffer from bone loss and skeletal-related adverse effects (Greenspan et al. 2005, Bruder et al.2006, Morote et al.2006, 2007), and a recent clinical report disclosed a negative correlation between skeletal fractures and overall survival in ADT-treated patients with PCa (Oefelein et al. 2002). These observations have led to the suggestion that clinicians should be alert to the impact of ADT on bone mineral density (BMD) and should strive to prevent bone loss. One limitation of the studies examining the relationship between ADT treatment and BMD is that most focused on Caucasian or black patients with PCa. Several studies have shown that Japanese and Caucasian women show racial differences in BMD and the incidence of bone fracture (Shimizu et al. 1990, Ito et al. 1997, Yoneda et al. 2006). One of these studies revealed that Japanese women have a lower BMD and a lower threshold of bone fracture than Caucasian women (Ito et al. 1997). These racial differences between Caucasian and Japanese women were also highlighted by a breast cancer study that showed that aromatase inhibitor treatment of Japanese women only slightly reduced their estrogen levels whereas Caucasian women showed a large reduction in estrogen levels; thus, aromatase inhibitor treatment is less likely to affect bone turnover and BMD levels in Japanese women than in Caucasian women (Yoneda et al. 2006). These observations suggest that Japanese men could differ from Caucasian men in terms of the influence of ADT on BMD and bone metabolism. To test this notion, we here examined the effect of ADT on bone metabolism in Japanese patients with PCa. Materials and methods Subjects A total of 101 native Japanese patients with PCa were enrolled in this study. These patients comprised 58 ADT-treated and 43 hormone-naive patients who were treated at the Akita University Medical Center from December 2006 to November Of the 58 ADT-treated patients, 37 and 21 did and did not have bone metastasis respectively. Patients with bone metastases in the lumbar spine or the hip joint were not included in this study as these were the regions we subjected to BMD measurement. The subjects completed a baseline questionnaire regarding life-style factors, including caffeinated beverage servings per day, smoking status, packs per year of cigarettes smoked, alcoholic drinks per week, use of calcium and vitamin D supplements, and exercise (days per week and total hours per week). All PCa patients were diagnosed on the basis of histological analysis of specimens obtained from transrectal needle biopsy or transurethral resection of the prostate for voiding symptoms. All 58 patients who underwent surgical castration or received a luteinizing hormone-releasing hormone agonist were demonstrated to have castrated levels of serum testosterone. In addition, 48 of the 58 ADT-treated patients (82.8%) also received bicalutamide (80 mg/day). The pathological grading of PCa was determined according to Gleason s histological grading and the tumor node metastatic system (Gleason 1977, Sobin & Wittekind 2002). BMD measurements BMD was measured in our hospital in by dual energy X-ray absorptiometry (DXA) using a Delphi QDR (Hologic, Bedford, MA, USA). The area of BMD in grams per square centimeter was measured at the posteroanterior spine (L2 L4) and the non-dominant hip (the total hip and the femoral neck). Peak BMD, age-specific BMD, peak S.D., and age-specific S.D. for DXA values were derived from the Hologic database for East Asian ethnicity (version 2.0; Hologic, Inc). The coefficient of variation was less than 1%. BMD was expressed in S.D. units relative to young adult men (T-score) and relative to age-matched men (Z-score). According to World Health Organization criteria, a normal BMD is defined as a T-score greater than K1 S.D.s, osteopenia as a T-score between K1 and K2.5, and osteoporosis as a T-score of K2.5 or less (Miller 2006). Measurement of biochemical values The serum levels of N-terminal telopeptide of type I collagen (NTx, normal range nmol/l), C-terminal telopeptides of type I collagen (ICTP, normal range ng/ml), intact parathyroid hormone (intact PTH, normal range pg/ml), prostate-specific antigen (PSA, normal range less than 4 ng/ml), and testosterone (normal range ng/ml) were measured before breakfast at the time BMD was measured. The intraassay coefficients of variation for NTx and ICTP were less than 10 and 8% respectively. In addition, common laboratory blood and serum data, including hemoglobin (Hb), albumin (Alb), lactate dehydrogenase (LDH), alkaline phosphatase (ALP), Ca, P, and glucose (Glu) levels, were determined using a multichannel autoanalyzer (LX-20, Beckman-Coulter, Los Angeles, CA, USA). Statistical analysis Differences in the clinical and serum variables of the hormone-naive patients, the ADT-treated patients 944
3 Endocrine-Related Cancer (2008) without bone metastasis, and the ADT-treated patients with bone metastasis were evaluated using the Student s t-test. Alternatively, the Mann Whitney U test was used if the group variances were unequal or the dependent variables were non-normally distributed and not transformable. The groups were also compared with regard to the prevalences of normal BMDs, osteopenia, osteoporosis, and life-style factors and analyzed statistically using the Kruskal Wallis test. Univariate analysis was used to assess the association between BMD and age, body mass index (BMI), serum PSA levels, presence or absence of ADT, and duration of ADT. Multivariate backward stepwise linear regression analysis was performed to identify the parameters that were independently and significantly associated with BMD. Nonparametric Spearman rank-order correlation coefficients were calculated to investigate the relationship between the BMD, T-score, and Z-score and a variety of bone metabolic markers. A modest positive correlation was considered to be an r value of , whereas a strong correlation was considered to be an r value greater than 0.5. All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS version 13.0; SPSS Inc, Chicago, IL, USA) and two-sided P values less than 0.05 were considered to indicate statistical significance. Results Patient characteristics The 101 patients were divided into hormone-naive patients (nz43), ADT-treated patients without bone metastasis (nz37), and ADT-treated patients with bone metastasis (nz21) and their characteristics, including their age, BMI, biopsy Gleason score, serum or blood levels of Alb, Hb, PSA and testosterone, and the presence and duration of ADT, are summarized in Table 1. In addition, the life-style factors of these patients, including caffeinated beverage consumption, smoking status, alcoholic drink consumption, use of calcium and vitamin D supplements, and exercise, are summarized in Table 1. The ADT-treated patients without bone metastasis were significantly older than the other two groups, while the the ADT-treated patients with bone metastasis tended to have higher serum PSA values than those without bone metastasis (PZ0.053). The ADT-treated patients without bone metastasis tended to have higher serum LDH values than the hormone-naive patients (PZ0.054), while the hormone-naive patients had significantly higher serum levels of testosterone than the two ADT-treated groups. However, all three groups were similar in terms of the other variables that were recorded, including BMI, Gleason score, Hb and serum levels of Alb and Glu (Table 1). They also did not differ significantly in terms of the life-style factors that were recorded, including caffeinated beverage consumption, smoking status, packs per year of cigarettes, alcohol consumption, calcium or vitamin D supplementation, and exercise (Table 1). Comparison of the BMDs, T-scores, and Z-scores of the hormone-naive and ADT-treated patients According to new guidelines, osteoporosis can be diagnosed when DXA of the lumbar spine, total hip, or femoral neck yields a T-score of K2.5 or less (Miller 2006). Therefore, we measured the BMD at these three sites in this study. Since bone metastatic lesions can affect the BMD results, we initially excluded the bone metastatic patients and compared the BMDs, T-scores, and Z-scores of the hormone-naive patients and the ADT-treated patients without bone metastasis (Table 2). In addition, when calculating T-score, the International Society of Clinical Densitometry recommends to use a uniform Caucasian (non-race adjusted) male normative database for men of all ethnic groups, although they also described that the application of recommendation may vary according to the local requirement. On current, there is no consensus of the database in calculating T-score of the patients under ADT. Therefore, we used both databases when calculating T-scores in this study. The BMD values and T-scores at the three sites of the ADT-treated patients were all lower than those of the hormone-naive patients, although these differences did not achieve statistical significance (Table 2). In the International Society of Clinical Densitometry recommendation, the patient s self-reported ethnicity should be used when calculating Z-scores. The average Z-scores (which indicate the S.D. units compared with age-matched normal relatives) of the ADT-treated patients and the hormone-naive patients were positive in this study. Prevalence of osteoporosis and osteopenia in the hormone-naive and ADT-treated patients We compared the prevalence of osteoporosis and osteopenia in the hormone-naive patients and the ADT-treated patients without bone metastasis (Table 3). At first, in order to decide the prevalence of osteopenia and osteoporosis, we calculated T-scores using East Asian database (Table 3). When focusing on the worst site showing low T-score, the prevalence of osteoporosis and osteopenia for the hormone-naive PCa patients was 2.3% (1 patient) and 44.2% (19 patients) respectively. By contrast, for the ADT-treated PCa patients, the respective prevalence was 10.8% (4 patients) and 40.6% (15 patients). These differences were not 945
4 946 Table 1 Comparison of the characteristics and lifestyle factors of the three groups of patients with prostate cancer Under androgen-deprivation therapy (ADT) Hormone-naive Bone metastasis (K) (nz43) Bone metastasis (K) (nz37) Bone metastasis (C) (nz21) P a P b (A) Comparison of the characteristics of the three groups of patients with prostate cancer Age 68.1G G G Body mass index (kg/m 2 ) 23.4G G G Biopsy Gleason score 7.2G G G PSA (ng/ml) 10.3G G G Hemoglobin (g/dl) 12.6G G G Albumin (g/dl) 4.1G G G Glucose (g/dl) 112.8G G G LDH (IU/l) 171.7G G G Testosterone (ng/ml) 4.1G G G !10 K Duration of ADT (month) 23.5G G (B) Comparison of the life-style factors of the three groups of patients with prostate cancer Caffeinated beverages/day (40%) 14 (38%) 11 (52%) (49%) 16 (43%) 3 (14%) R3 5 (11%) 3 (8%) 2 (10%) Unknown 0 (0%) 4 (11%) 5 (24%) Smoking status Never 27 (63%) 18 (49%) 10 (47%) Former 12 (28%) 18 (49%) 6 (29%) Current 4 (9%) 1 (2%) 0 (0%) Unknown 0 (0%) 0 (0%) 5 (24%) Packs per year of cigarettes (63%) 18 (49%) 10 (47%)!20 14 (33%) 13 (35%) 6 (29%) R20 2 (4%) 6 (16%) 0 (0%) Unknown 0 (0%) 0 (0%) 5 (24%) Alcohol (drinks/week) (44%) 14 (38%) 8 (38%) (21%) 8 (22%) 2 (10%) R7 15 (35%) 15 (41%) 6 (29%) Unknown 0 (0%) 0 (0%) 5 (24%) Calcium supplements No 41 (95%) 31 (84%) 15 (71%) Yes 2 (5%) 6 (16%) 1 (5%) Unknown 0 (0%) 0 (0%) 5 (24%) Vitamin D supplements No 40 (93%) 33 (89%) 15 (71%) Yes 3 (7%) 4 (11%) 1 (5%) Unknown 0 (0%) 0 (0%) 5 (24%) W Wang et al.: BMD in Japanese prostate cancer patients
5 Endocrine-Related Cancer (2008) Table 1 continued Under androgen-deprivation therapy (ADT) Hormone-naive Bone metastasis (K) (nz43) Bone metastasis (K) (nz37) Bone metastasis (C) (nz21) P a P b Exercise (days/week) (37%) 18 (49%) 7 (33%) (30%) 8 (22%) 4 (19%) (33%) 9 (24%) 5 (24%) Unknown 0 (0%) 2 (5%) 5 (24%) Exercise (h/week) (37%) 18 (49%) 7 (33%)!2 8 (19%) 7 (19%) 4 (19%) R2 19 (44%) 10 (27%) 5 (24%) Unknown 0 (0%) 2 (5%) 5 (24%) Values indicate meangs.d. The data are presented as number of patients (percentages). a Probability values of the differences between the hormone-naive patients and the ADT-treated patients without bone metastasis. b Probability values of the differences between the ADT-treated patients with and without bone metastasis. significant. In addition, we also decided the prevalence of osteopenia and osteoporosis using Caucasian database. We found that the differences of the prevalence of osteopenia and osteoporosis were also not significant (Supplementary Table 1, which can be viewed online at These results suggest that the PCa patients without bone metastasis did not show a significant increase in the prevalence of osteoporosis and osteopenia after a relatively short period of ADT (average 23.5 months). Association of the ADT duration with BMD, T-score, and Z-score of the patients with non-metastatic PCa A study examining the BMD of Caucasian patients with PCa revealed that the greatest ADT-induced bone loss occurred in the first 12 months, after which time it showed a slower decrease (Bunker et al. 2006). To determine whether Japanese PCa patients showed a similar pattern, we investigated the association between the duration of ADT and BMD, the T-score, and the Z-score in ADT-treated patients with non-metastatic PCa (Fig. 1). For all three sites measured (L2 L4 spine, femoral neck, and total hip joint), a significant correlation between the duration of ADT and BMD was not observed (rzk0.152, PZ0.147; rzk0.020, PZ0.850; and rzk0.045, PZ0.670, respectively). To determine whether other patient characteristics were associated with the lower BMD in ADT-treated men, we performed a series of regression analyses using the data from the ADT-treated PCa patients without metastasis. BMD was weakly positively correlated with BMI (rz0.379, PZ0.001) and weakly inversely correlated with age (rzk0.337, PZ0.004). However, no other factors correlated significantly with the BMD at any of the three sites, including the serum PSA levels, the biopsy Gleason score, the presence or absence of ADT, and the duration of ADT. Furthermore, none of these factors, including ADT, were independent predictors in a multivariate linear regression model using the BMDs at the three sites. These observations together suggest that ADT does not have a big impact on BMD in Japanese patients. Influence of ADT on serum variables and bone metabolism To determine the effect of ADT on serum variables associated with bone metabolism, we compared the hormone-naive patients and the ADT-treated patients without metastasis with regard to these variables. As shown in Table 4, the ADT-treated patients had significantly higher serum levels of NTx, which reflects bone resorption, than the hormone-naive patients 947
6 W Wang et al.: BMD in Japanese prostate cancer patients Table 2 Comparison of the bone mineral density (BMD), T-score, and Z-score of the three groups of patients with prostate cancer Under androgen-deprivation therapy (ADT) Hormone naive Bone metastasis (K) Bone metastasis (K) Bone metastasis (C) P a P b Lumbar spine (PA) BMD 1.050G G G T-score (East Asian) c 0.037G1.603 K0.465G1.482 K0.300G T-score (Caucasian) d K0.573G2.082 K1.350G1.599 K1.300G Z-score 0.593G G G Femoral neck BMD 0.763G G G T-score (East Asian) c K0.793G0.900 K0.981G0.863 K0.829G T-score (Caucasian) d K1.206G0.669 K1.443G0.846 K1.313G Z-score 0.408G G G Total hip BMD 0.891G G G T-score (East Asian) c K0.512G1.066 K0.820G0.990 K0.619G T-score (Caucasian) d K0.918G0.792 K1.312G0.870 K1.035G Z-score 0.519G G G Values indicate meangs.d. a Probability values of the differences between the hormone-naive patients and the ADT-treated patients without bone metastasis. b Probability values of the differences between the ADT-treated patients with and without bone metastasis. c T-score calculated with East Asian database. d T-score calculated with Caucasian database. (PZ0.017) but the two groups did not differ significantly in any of the other serum variables. Next, we investigated the association between the bone mineral variables (BMD, T-score, Z-score) and the serum variables associated with bone metabolism (PSA, Ca, P, ALP, NTx, ICTP, and intact PTH). The serum NTx level was the only variable that was significantly associated with the BMDs of all three sites that were measured (L2 L4 spine, femoral neck, and total hip joint), although the correlations were relatively weak (rzk0.330, PZ0.005; rzk0.338, PZ0.004; and rzk0.434, PZ0.0001, respectively). Thus, while ADT is only weakly associated with BMD loss, it is significantly associated with increased serum NTx levels. Table 3 Comparison of the frequencies of osteoporosis and osteopenia of the three groups of patients with prostate cancer a Under androgen-deprivation therapy (ADT) Hormone-naive Bone metastasis Bone metastasis (K) Bone metastasis (C) P b P c Lumbar spine (PA) Normal 31 (72.1%) 22 (59.5%) 15 (71.4%) Osteopenia 11 (25.6%) 11 (29.7%) 5 (23.8%) Osteoporosis 1 (2.3%) 4 (10.8%) 1 (4.8%) Femoral neck Normal 23 (53.5%) 18 (48.6%) 13 (61.9%) Osteopenia 19 (44.2%) 18 (48.6%) 7 (33.3%) Osteoporosis 1 (2.3%) 1 (2.7%) 1 (4.8%) Total hip Normal 34 (79.1%) 22 (59.5%) 14 (66.7%) Osteopenia 8 (18.6%) 12 (32.4%) 6 (28.6%) Osteoporosis 1 (2.3%) 3 (8.1%) 1 (4.8%) Worst site Normal 23 (53.5%) 18 (48.6%) 13 (61.9%) Osteopenia 19 (44.2%) 15 (40.6%) 7 (33.3%) Osteoporosis 1 (2.3%) 4 (10.8%) 1 (4.8%) Values indicate the numbers (percentile). a T-scores were calculated with East Asian database. b Probability values of the differences between the hormone-naive patients and the ADT-treated patients without bone metastasis. c Probability values of the differences between the ADT-treated patients with and without bone metastasis
7 Endocrine-Related Cancer (2008) Figure 1 Association between the duration of androgen-deprivation therapy and the BMD, T-score, and Z-score of the lumbar spine, femoral neck, and total hip joints. This suggests that measuring NTx levels may be a better way of monitoring bone loss in Japanese patients. Comparison of the BMDs, T-scores, and Z-scores of the ADT-treated patients with and without bone metastasis Osteoblastic metastatic lesions, which are typical in patients with bone metastasis and PCa, may artificially increase the BMD score. To determine the extent to which the presence of bone metastasis influences the BMD, we compared the clinical parameters of the ADT-treated patients with and without bone metastasis (Tables 2 and 3). These two groups of patients did not differ significantly in BMDs, T-scores, or Z-scores, which suggest that the DXA-measured BMD values of patients with PCa are not disturbed by the presence of bone metastases. Moreover, the two groups of ADT-treated patients did not differ significantly in their serum NTx levels (Table 4), which indicates that the NTx serum levels reflect the effect of ADT on bone resorption and are not altered by the presence of bone metastases. Table 4 Comparison of the serum variables of the three groups of patients with prostate cancer Under androgen-deprivation therapy (ADT) Hormone naive Bone metastasis (K) Bone metastasis (K) Bone metastasis (C) P a P b ALP (IU/l) 227.5G G G Calcium (mg/dl) 8.9G G G Phosphate (mg/dl) 3.2G G G Intact PTH (pg/ml) 34.5G G G NTx (nmol/l) 13.3G G G ICTP (ng/ml) 5.1G G G Values indicate meangs.d. a Probability values of the differences between the hormone-naive patients and the ADT-treated patients without bone metastasis. b Probability values of the differences between the ADT-treated patients with and without bone metastasis
8 W Wang et al.: BMD in Japanese prostate cancer patients Discussion The effect of ADT on BMD and its ability to induce osteoporosis in Caucasians and blacks, mainly in western countries, are now well documented (Greenspan et al. 2005, Bruder et al. 2006, Morote et al. 2006, 2007). However, it remains unclear whether ADT has a similar influence on the BMD of East Asian patients with PCa. Although other studies found a high incidence of osteoporosis in western ADT-treated patients with PCa (Bruder et al. 2006, Morote et al. 2006, 2007), we found that this was not true for Japanese patients with PCa, as only 10.8% (4/37) of the ADT-treated patients exhibited osteoporosis. However, ADT did mildly promote osteoporosis in Japanese PCa patients, as even fewer of the hormone-naive PCa patients (2.3%; 1/43) had osteoporosis, although this difference from ADT-treated patients did not quite achieve statistical significance (PZ0.294). In addition, since there was no correlation between the duration of ADT and BMD or other parameters, our study suggested that longer durations of ADT do not significantly decrease the BMD of Japanese PCa patients and therefore may not increase the prevalence of osteoporosis in these patients. It is possible that we did not detect a significant difference in BMD between ADT-treated and hormone-naive PCa patients (PZ0.294) because the patients in this study only received ADT for a relatively short period (on average 23.5 months). However, many studies of Caucasian patients with PCa have shown high incidences of osteoporosis in patients receiving ADT for similarly short durations; moreover, even ADT-naive Caucasian patients show a high incidence of osteoporosis (Bruder et al. 2006, Morote et al. 2006, 2007). For example, Bruder et al. (2006) showed that of 89 patients with a median duration of ADT of 2.7G2.5 years, whose BMDs in the spine and total hip had been measured, 26.9 and 50.6% had osteoporosis and osteopenia respectively. Moreover, Morote et al. (2007) reported that 35.4 and 45.2% of hormone-naive patients had osteoporosis and osteopenia respectively (Morote et al. 2007), while 42.9 and 39.3% of patients that had been treated with ADT for 2 years suffered osteoporosis and osteopenia respectively. They also showed that the greatest bone loss occurred in the first year after the initiation of androgen deprivation (Morote et al. 2006). Thus, it is unlikely that the relatively short duration of ADT in our study explains why we did not detect a significant difference between hormone-naive and ADT-treated Japanese patients with PCa. Moreover, it appears that Caucasians have a higher baseline incidence of BMD loss and a higher susceptibility to ADT-induced bone loss than Japanese patients. Only two other studies have sought to evaluate the BMD in Japanese patients with PCa (Egawa et al. 2000, Miyaji et al. 2004). Miyaji et al. (2004) showed that 27 patients with PCa exhibited mild but significant bone loss after being treated for 2 years with ADT using gonadotropin-releasing hormone agonists, as their median BMD dropped from to g/cm 2 (PZ0.047). Egawa et al. (2000) reported a pilot study of 17 patients with PCa treated intermittently with ADT and stated that 10 (58.8%) patients maintained BMD levels in the normal range for their age. However, neither of these studies measured the rates of osteoporosis in these patients. Thus, we show here for the first time that Japanese PCa patients suffer low rates of osteoporosis regardless of whether they are treated with ADT. We also observed that the average Z-score of the patients under ADT was not lower than that of hormone-naive patients, and that these average Z-scores of the hormone-naive patients and the ADT-treated patients with and without bone metastasis were positive. These results indicate that the average BMDs of the patients in this study were higher than that of age-matched East Asian controls. While this could reflect a selection bias, it could also suggest that Japanese men with high baseline BMDs have a higher propensity to develop PCa. This notion is supported by a recent report showing that high bone density in older Afro-Caribbean men is associated with PCa (Bunker et al. 2006). However, other studies in western countries have not observed this trend (Bruder et al. 2006, Morote et al. 2006, 2007). The reasons for these differences between Caucasians, westerners, and Japanese are not clear but may reflect racial differences in the genetic factors that determine the BMD. Treatment and life-style factors may also be important determinants that drive these differences. Another important finding of this study was that the mean serum NTx level of non-metastatic patients under ADT was significantly higher than that of hormone-naive patients (PZ0.017). Serum NTx levels reflect bone resorption and our observation is consistent with our other finding that ADT treatment of Japanese PCa patients mildly increases the loss of BMD, although this difference did not achieve statistical significance (PZ0.294). Notably, we also showed that the NTx serum levels of the ADT-treated patients correlated weakly but significantly with BMD (rz0.379, PZ0.001). These observations suggest that serum NTx can reflect the impact of ADT on bone resorption more precisely than BMD and that detection 950
9 Endocrine-Related Cancer (2008) of an increase in serum NTx in ADT patients may herald a significant decrease in bone mass. Further investigations are needed to confirm the correlation of NTx and BMD under ADT. It should be noted that ADT and bone metastasis frequently coexist in PCa patients and that osteoblastic metastatic lesions may artificially increase the BMD. Supporting this is that regions with osteoblastic bone metastasis show significantly higher bone density than regions with osteolytic bone lesions (Vassiliou et al. 2007). These observations have led many BMD studies to exclude patients with bone metastasis. It also led us to exclude patients with hot spots in the lumbar spine or the hip joint (which are the bone regions we evaluated in this study) and to separate the ADT-treated patients with bone metastasis from those without bone metastasis. Significantly, however, we did not detect any differences in BMD or serum NTx levels between ADT-treated PCa patients with or without bone metastasis. This is consistent with a report by Michaelson et al. (2004) that showed the serum NTx levels of ADT-treated PCa patients were significantly higher than those of hormone-naive men (P!0.01) but did not differ when bone metastasis was present (PZ0.33). Thus, the effects of bone metastases on bone metabolism do not seem to disturb the DXA measurement of BMD or the serum NTx values. The presence of bone metastases also did not perturb other serum variables reflecting bone metabolism. That the patients with and without bone metastasis had comparable BMDs is important. One of the main reasons for measuring the BMD of patients with PCa is to enhance the early detection of pathological BMD loss, which allows appropriate treatment for osteoporosis to be instituted, which in turn reduces the incidence of bone fractures. Patients with bone metastases have the highest risk for bone fracture because they bear many risk factors, including older age, treatment with ADT, corticosteroid use, and bone metastasis (Higano 2003, Nelson 2006). Our observations suggest that we may be able to use DXA to evaluate the BMD of PCa patients with bone metastasis if it is properly conducted. In conclusion, our study showed that Japanese PCa patients did not have high rates of low BMD, regardless of whether they were hormone-naive or treated with ADT. We also did not detect an association between the length of ADT and BMD, T-score, or Z-score. These findings are quite different from previous studies examining patients in western countries. To our knowledge, this is the first study to demonstrate the low rates of osteoporosis in both ADT-treated and hormone-naive Japanese PCa patients. Given the cross-sectional nature of this study and its relatively small sample size, it will be necessary to conduct further larger scale and prospective studies to confirm our observations and to determine the genetic background and life-style factors that influence the BMD of PCa patients. Declaration of interest The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. Funding This work was partly supported by Kobayashi Institute for Innovative Cancer Chemotherapy, the Shimadzu Science Foundation, the Sagawa Foundation for Promotion of Cancer Research, the Japan-China Sasakawa Medical Fellowship, Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and the GCOE program of the Ministry of Education, Culture, Sports, Science and Technology, Japan. References Bruder JM, Ma JZ, Basler JW & Welch MD 2006 Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology Bunker CH, Zmuda JM, Patrick AL, Wheeler VW, Weissfeld JL, Kuller LH & Cauley JA 2006 High bone density is associated with prostate cancer in older Afro-Caribbean men: Tobago prostate survey. Cancer Causes and Control Cooperberg MR, Grossfeld GD, Lubeck DP & Carroll PR 2003 National practice patterns and time trends in androgen ablation for localized prostate cancer. Journal of the National Cancer Institute Egawa S, Takashima R, Matsumoto K, Mizoguchi H, Kuwao S & Baba S 2000 A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men. Japanese Journal of Clinical Oncology Gleason DF 1977 Histological grading and clinical staging of prostate carcinoma. In Urologic Pathology, pp Ed M Tannenbaum. Philadelphia: Lea & Feiger. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL & Resnick NM 2005 Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. Journal of Clinical Endocrinology and Metabolism Higano CS 2003 Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology
10 W Wang et al.: BMD in Japanese prostate cancer patients Huggins C & Hodges VC 1941 Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research International Union Against Cancer 2002 Urological tumors: prostate. In TNM Classification of Malignant Tumors, edn 6, pp Eds LH Sobin & C Wittekind. New York: Wiley-Liss. Ito M, Lang TF, Jergas M, Ohki M, Takada M, Nakamura T, Hayashi K & Genant HK 1997 Spinal trabecular bone loss and fracture in American and Japanese women. Calcified Tissue International Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di SantAgnese PA, Trump D & Eastern Cooperative Oncology Group study EST Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncology Michaelson MD, Marujo RM & Smith MR 2004 Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clinical Cancer Research Miller PD 2006 Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Reviews in Endocrine and Metabolic Disorders Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S, Nasu Y, Tsushima T & Kumon H 2004 Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G & Reventos J 2006 Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. Journal of Urology Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G & Reventos J 2007 Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology Nelson JB 2006 Hormonal therapy for prostate cancer. In Campbell-Walsh UROLOGY, edn 9, pp Eds AJ Wein, LR Kavoussi, AC Novick, AW Partin & CA Peters. New York: Elsevier. Oefelein MG, Ricchiuti VS, Conrad PW, Goldman H, Bodner D, Resnick MI & Seftel A 2002 Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era. Urology Shahinian VB, Kuo YF, Freeman JL & Goodwin JS 2005 Risk of fracture after androgen deprivation for prostate cancer. New England Journal of Medicine Sharifi N, Gulley JL & Dahut WL 2005 Androgen deprivation therapy for prostate cancer. Journal of the American Medical Association Shimizu H, Ross RK, Bernstein L, Pike MC & Henderson BE 1990 Serum oestrogen levels in postmenopausal women: comparison of American whites and Japanese in Japan. British Journal of Cancer Smith MR 2004 Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. Journal of Urology 172 S52 S56. Vassiliou V, Kalogeropoulou C, Petsas T, Leotsinidis M & Kardamakis D 2007 Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between clinical status of patients and type of bone metastases? Clinical & Experimental Metastasis Yoneda K, Tanji Y, Okishiro M, Taguchi T, Tamaki Y & Noguchi S 2006 Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference? Annals of Oncology
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
More informationClinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog
Hindawi Publishing Corporation Prostate Cancer Volume 2, Article ID 7664, 7 pages doi:.55/2/7664 Clinical Study Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing
More informationThe relationship between daily calcium intake and bone mineral density in men with prostate cancer
Original Article DAILY CALCIUM INTAKE AND BONE MINERAL DENSITY IN PROSTATE CANCER PLANAS ET AL. The relationship between daily calcium intake and bone mineral density in men with prostate cancer Jacques
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationBody composition changes during androgen deprivation therapy for prostate cancer: A 2-year prospective study
Critical Reviews in Oncology/Hematology 68 (2008) 172 177 Body composition changes during androgen deprivation therapy for prostate cancer: A 2-year prospective study Gijsberta J. van Londen a,, Matthew
More informationHOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationSkeletal complications of ADT: disease burden and treatment options
(2012) 14, 670 675 ß 2012 AJA, SIMM & SJTU. All rights reserved 1008-682X/12 $32.00 www.nature.com/aja REVIEW Skeletal complications of ADT: disease burden and treatment options Jacques Planas Morin and
More informationReview Article RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
SAGE-Hindawi Access to Research Osteoporosis Volume 2011, Article ID 941310, 6 pages doi:10.4061/2011/941310 Review Article RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationBone Mineral Density and Its Associated Factors in Naresuan University Staff
Naresuan University Journal 2005; 13(3): 13-18 13 Bone Mineral Density and Its Associated Factors in Naresuan University Staff Supawitoo Sookpeng *, Patsuree Cheebsumon, Malinee Dhanarun, Thanyavee Pengpan
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationName of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb ligand
Page 2 of 1765 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Denosumab (AMG 162) Name of Active Ingredient: Fully human monoclonal antibody to receptor activator for nuclear factor-κb
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationEuropean Journal of Endocrinology (1997) ISSN
European Journal of Endocrinology (1997) 137 167 171 ISSN 0804-4643 Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing
More informationNew Tools for the Urologist in the Management of Patients with Bone Metastases
european urology supplements 6 (2007) 689 694 available at www.sciencedirect.com journal homepage: www.europeanurology.com New Tools for the Urologist in the Management of Patients with Bone Metastases
More informationHanan Shawky 1 and Tarek Gamil 2.
Relationship of Combined Androgen Deprivation Therapy and Bone Turnover Markers with Bone Mineral Density, Lean Body Mass and Fat Content in Patients with Non- Metastatic Prostate Cancer Hanan Shawky 1
More informationCorrelation between Thyroid Function and Bone Mineral Density in Elderly People
IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationToremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Matthew R. Smith,*,, Ronald A. Morton,* K. Gary Barnette,* Paul R. Sieber, S. Bruce Malkowicz, Domingo
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationBone Mineral Density in Thai Patients with Chronic Hepatitis C, before and after Treatment with Pegylated Interferon/Ribavirin Combination ABSTRACT
Original Article 73 before and after Treatment with Pegylated Interferon/Ribavirin Combination Bunchorntavakul C 1 Chotiyaputta W 1 Sriussadaporn S 2 Tanwandee T 1 ABSTRACT Background: Loss of bone mineral
More informationExercise as Medicine for Cancer Management. Robert U. Newton, PhD
Exercise as Medicine for Cancer Management Robert U. Newton, PhD What is Anabolic Exercise? Repetitive movements performed against resistance Resistance limits number completed e.g. 10 reps per set (10RM)
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationAETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents
AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For
More informationRisk of Fracture after Androgen Deprivation for Prostate Cancer
The new england journal of medicine original article Risk of Fracture after Androgen Deprivation for Prostate Cancer Vahakn B. Shahinian, M.D., Yong-Fang Kuo, Ph.D., Jean L. Freeman, Ph.D., and James S.
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationVivek K. Wadhwa, Robin Weston and Nigel J. Parr Department of Urology, Wirral University Teaching Hospitals, Wirral, UK
21 THE AUTHORS; 21 Urological Oncology BICALUTAMIDE MONOTHERAPY IN PROSTATE CANCER WADHWA ET AL. BJUI Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationLOVE YOUR BONES Protect your future
www.worldosteoporosisday.org LOVE YOUR BONES Protect your future Know your risk for osteoporosis www.iofbonehealth.org Osteoporosis is a problem worldwide, and in many countries, up to one in three women
More informationA comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients
ONCOLOGY LETTERS 14: 299-305, 2017 A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients KOICHI SHOJI 1, JUN TEISHIMA 1, TETSUTARO
More informationEffect of Precision Error on T-scores and the Diagnostic Classification of Bone Status
Journal of Clinical Densitometry, vol. 10, no. 3, 239e243, 2007 Ó Copyright 2007 by The International Society for Clinical Densitometry 1094-6950/07/10:239e243/$32.00 DOI: 10.1016/j.jocd.2007.03.002 Original
More informationDepartment of Urology, Kitasato University School of Medicine 2
Original Contribution Kitasato Med J 2012; 42: 51-56 The impact of urinary cross-linked N-telopeptide of type I collagen in patients with prostate cancer receiving long-term risedronate treatment and androgen-deprivation
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationRisk of renal side effects with ADT. E. David Crawford University of Colorado, Aurora, CO, USA
Risk of renal side effects with ADT E. David Crawford University of Colorado, Aurora, CO, USA ADT: A key treatment for advanced prostate cancer John Hunter 1780-castration 1904: First RP 1938: Acid Phos.
More informationAromatase Inhibitors & Osteoporosis
Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health
More informationRESEARCH ARTICLE. Hui Ding 1, Li Yang 1, Wan Du 2, Yang Teng 3, Sheng-Jun Fu 1, Yan Tao 1, Jian-Zhong Lu 1, Zhi-Ping Wang 1,4 * Abstract.
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.5.3337 RESEARCH ARTICLE Bisphosphonates for Osteoporosis in Nonmetastatic Prostate Cancer Patients Receiving Androgen-deprivation Therapy: A Systematic Review
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationMedical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?
ORIGINAL PAPER DOI: 10.4081/aiua.2017.4.282 Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels? Murat Bagcioglu
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationBone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome
Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome Thomas et al. Nutrition Journal (2015) 14:99 DOI 10.1186/s12937-015-0092-2 RESEARCH Open Access Acute effect of a supplemented
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationElderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationClinical Study Comparison of QCT and DXA: Osteoporosis Detection Rates in Postmenopausal Women
International Endocrinology Volume 3, Article ID 895474, 5 pages http://dx.doi.org/.55/3/895474 Clinical Study Comparison of QCT and DXA: Osteoporosis Detection Rates in Postmenopausal Women Na Li, Xin-min
More informationBONE HEALTH Dr. Tia Lillie. Exercise, Physical Activity and Osteoporosis
BONE HEALTH Dr. Tia Lillie Exercise, Physical Activity and Osteoporosis Food for thought... How old would you be if you didn t know how old you were? DEFINITION: Osteoporosis Osteoporosis (OP) is a disease
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationDEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN
October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.
More informationKobe University Repository : Kernel
Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms
More informationMedication Associated Osteoporosis
Medication Associated Osteoporosis Drugs that are bad for the bones Jonathan Graf, MD Associate Professor of Clinical Medicine UCSF Director UCSF Rheumatoid Arthritis Clinic Necessary Therapies Preventable
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationBone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationApproach to a patient with hypercalcemia
Approach to a patient with hypercalcemia Ana-Maria Chindris, MD Division of Endocrinology Mayo Clinic Florida 2013 MFMER slide-1 Background Hypercalcemia is a problem frequently encountered in clinical
More informationAndrogen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Celestia S Higano SUMMARY Androgen deprivation therapy (ADT) alone or in combination with
More informationINTRODUCTION PATIENTS AND METHODS. Jpn J Clin Oncol 2007;37(10) doi: /jjco/hym098
Jpn J Clin Oncol 2007;37(10)775 781 doi:10.1093/jjco/hym098 Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationBone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score
Kawahara et al. BMC Urology (2016) 16:32 DOI 10.1186/s12894-016-0151-9 RESEARCH ARTICLE Bone management in Japanese patients with prostate cancer: hormonal therapy leads to an increase in the FRAX score
More informationPRO STATE of the art. METASTATIC HORMONE SENSITIVE PROSTATE CANCER Clinical case and evidences from literature
PRO STATE of the art METASTATIC HORMONE SENSITIVE PROSTATE CANCER Clinical case and evidences from literature Marcello Tucci, MD Department of Oncology San Luigi Gonzaga Hospital Orbassano, Turin 30 MAY
More informationOsteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made?
A New Type of Patient Rafat Faraawi, MD, FRCP(C), FACP Until recently, the diagnosis of osteoporosis in men was uncommon and, when present, it was typically described as a consequence of secondary causes.
More informationNeed for Measurement of Bone Mineral Density in Patients of Prostate Cancer Before and After Orchidectomy: Role of Quantitative Computer Tomography
Original Article Need for Measurement of Bone Mineral Density in Patients of Prostate Cancer Before and After Orchidectomy: Role of Quantitative Computer Tomography MM Agarwal*, AK Mandal**, N Khandelwal**,
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationUse of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
More informationLa salute dell osso nelle pazienti in trattamento adiuvante. Airoldi Mario - S.C. Oncologia Medica 2 Città della Salute e della Scienza di Torino
La salute dell osso nelle pazienti in trattamento adiuvante Airoldi Mario - S.C. Oncologia Medica 2 Città della Salute e della Scienza di Torino BONE STRENGTH OSTEOPOROSIS SKELETAL DISORDER COMPROMISING
More informationChapter 39: Exercise prescription in those with osteoporosis
Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationDiagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.
Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationMODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT
MODULE 8: PROSTATE CANCER: SCREENING & MANAGEMENT KEYWORDS: Prostate cancer, PSA, Screening, Radical Prostatectomy LEARNING OBJECTIVES At the end of this clerkship, the medical student will be able to:
More informationDXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi
DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi Clinical Utility of Bone Densitometry Diagnosis (DXA)
More informationCommunity care of Prostate Cancer. Shaun Costello Southern Cancer Network
Community care of Prostate Cancer Shaun Costello Southern Cancer Network Introduction Why is GP follow up of prostate cancer important 4Years In Waikato Faster Cancer Treatment Reporting against the 3
More informationChanges in Bone Mineral Density and Metabolism in Women: Evaluation of bodily characteristics, bone metabolic markers and bone mineral density
Hiroshima J. Med. Sci. Vol. 62, No. 3, 49~53, September, 2013 HIJM 62 9 49 Changes in Bone Mineral Density and Metabolism in Women: Evaluation of bodily characteristics, bone metabolic markers and bone
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationClinical features and treatment strategies for older prostate cancer patients with bone metastasis
(2013) 15, 759 763 ß 2013 AJA, SIMM & SJTU. All rights reserved 1008-682X/13 $32.00 www.nature.com/aja ORIGINAL ARTICLE Clinical features and treatment strategies for older prostate cancer patients with
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra
More informationA Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman
A Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman JY Han, et al CASE REPORT http://dx.doi.org/10.11005/jbm.2012.19.2.153 Vol. 19, No. 2, 2012 A Case of Cushing Syndrome
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More information